Navigation Links
China Biologic to Report Second Quarter 2014 Financial Results
Date:7/29/2014

BEIJING, July 29, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes.

The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, August 6, 2014, which is 8:00 p.m., Beijing Time on August 6, 2014, to discuss second quarter 2014 results. Listeners may access the call by dialing:

US:                                                       1 877 870 4263 
International:                                        1 412 317 0790   
Hong Kong:                                          800 905 945 
China:                                                  400 120 1203
Passcode:                                            China Biologic Products Inc.                   

A telephone replay will be available one hour after the conclusion of the conference call through 9:00 a.m., Eastern Time on August 13, 2014. The dial-in details are:

US:                                                        1 877 344 7529
International:                                         1 412 317 0088    
Passcode:                                             10050434                      

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products, Inc.

China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company's website www.chinabiologic.com .

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China
2. Orthopedic Instrument Industry in China Markets Forecast to 2015
3. EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
4. CareFusion Completes Vital Signs Acquisition In U.S., China
5. China Antidiabetic Drug Market 2014 Analysis & 2018 Forecasts
6. Research Report on Global and China Aerosol Industry, 2013-2017
7. Use of Roches Herceptin Among HER2+ Gastric Cancer Patients May Double in China Over the Next Three Years
8. China Pharmaceutical Guidebook: (2013 Edition) Latest Chinese Regulations for Imported Drug Registration
9. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
10. China Feed Additives Industry Report, 2012-2015
11. Lucintel Analysis: Medical Reforms and Aging Population to Offer Significant Growth Opportunities to China Oxygen Cylinders Industry Players
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits ... effects allegedly associated with use of the atypical antipsychotic ... Philadelphia Court of Common Pleas, where the ... tort program. According to a notice posted on the ... convene a meeting on March 9, 2017 at 11:00 ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume ... Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... can pick and choose from hand-crafted trend-setting designs with smooth animations that will ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
Breaking Medicine News(10 mins):